Denali Therapeutics (DNLI) had its price target raised by Robert W. Baird from $32.00 to $34.00. They now have an "outperform" rating on the stock.
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) [Yahoo! Finance]
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
This rare disease destroys a child's ability to walk and speak. Could a new drug help? [MSNBC.com]
They're in a race to save their children with a rare disease. A newly approved drug has given them hope. [MSNBC.com]